{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:46:21Z","timestamp":1787024781031,"version":"build-2736575974"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.2169\/internalmedicine.6139-25","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:06:06Z","timestamp":1763589966000},"page":"1625-1631","source":"Crossref","is-referenced-by-count":2,"title":["Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab"],"prefix":"10.2169","volume":"65","author":[{"given":"Sho","family":"Masaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Masuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Honjo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol 24: 559-576, 2024.","DOI":"10.1038\/s41577-024-01008-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol 10: 573-592, 2025.","DOI":"10.1016\/S2468-1253(24)00390-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Masaki S, Masuta Y, Honjo H, Kudo M, Watanabe T. NOD2-mediated dual negative regulation of inflammatory responses triggered by TLRs in the gastrointestinal tract. Front Immunol 15: 1433620, 2024.","DOI":"10.3389\/fimmu.2024.1433620"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Horowitz A, Chanez-Paredes SD, Haest X, Turner JR. Paracellular permeability and tight junction regulation in gut health and disease. Nat Rev Gastroenterol Hepatol 20: 417-432, 2023.","DOI":"10.1038\/s41575-023-00766-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci 44: 141-152, 2019.","DOI":"10.1016\/j.tibs.2018.09.008"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Zeissig S, B\u00fcrgel N, G\u00fcnzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn&apos;s disease. Gut 56: 61-72, 2007.","DOI":"10.1136\/gut.2006.094375"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Barrett KE. Claudin-2 pore causes leak that breaches the dam in intestinal inflammation. J Clin Invest 130: 5100-5101, 2020.","DOI":"10.1172\/JCI140528"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nakajima T, Tsuji H, Inaba R, Saito R, Nishimura K, Morinobu A. Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Beh\u00e7et&apos;s disease in a multicentre study. Mod Rheumatol 34: 1221-1225, 2024.","DOI":"10.1093\/mr\/roae022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakamura J, Meguro A, Ishii G, et al. The association analysis between <i>HLA-A*26<\/i> and Beh\u00e7et&apos;s disease. Sci Rep 9: 4426, 2019.","DOI":"10.1038\/s41598-019-40824-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 10: 989-997, 2016.","DOI":"10.1093\/ecco-jcc\/jjw053"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists. Cytokine 101: 56-63, 2018.","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-\u03b1 therapy increases the number of FOXP3<sup>+<\/sup> regulatory T cells in children affected by Crohn&apos;s disease. Immunology 125: 178-183, 2008.","DOI":"10.1111\/j.1365-2567.2008.02839.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yoshikawa K, Watanabe T, Sekai I, et al. Case report: a case of intestinal Behcet&apos;s disease exhibiting enhanced expression of IL-6 and forkhead box P3 mRNA after treatment with infliximab. Front Med (Lausanne) 8: 679237, 2021.","DOI":"10.3389\/fmed.2021.679237"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Masuta Y, Minaga K, Kurimoto M, et al. Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression. Int Immunol 35: 79-94, 2023.","DOI":"10.1093\/intimm\/dxac045"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chung H, Watanabe T, Kudo M, Chiba T. Hepatitis C virus core protein induces homotolerance and cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2. J Infect Dis 202: 853-861, 2010.","DOI":"10.1086\/655812"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Takada R, Watanabe T, Hara A, et al. NOD2 deficiency protects mice from the development of adoptive transfer colitis through the induction of regulatory T cells expressing forkhead box P3. Biochem Biophys Res Commun 568: 55-61, 2021.","DOI":"10.1016\/j.bbrc.2021.06.068"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Takai A, Marusawa H, Minaki Y, et al. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 31: 1733-1742, 2012.","DOI":"10.1038\/onc.2011.352"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Abraham C. Interleukin-23 p19 and interleukin-12 p40, head-to-head, against gut inflammation. N Engl J Med 391: 275-277, 2024.","DOI":"10.1056\/NEJMe2405452"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Raju P, Shashikanth N, Tsai PY, et al. Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice. J Clin Invest 130: 5197-5208, 2020.","DOI":"10.1172\/JCI138697"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tsai PY, Zhang B, He WQ, et al. IL-22 Upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance. Cell Host Microbe 21: 671-681. e674, 2017.","DOI":"10.1016\/j.chom.2017.05.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol 294: G938-G947, 2008.","DOI":"10.1152\/ajpgi.00469.2007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest 88: 1110-1120, 2008.","DOI":"10.1038\/labinvest.2008.78"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Hueber W, Sands BE, Lewitzky S, et al.; the Secukinumab in Crohn&apos;s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn&apos;s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61: 1693-1700, 2012.","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. D&apos;Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn&apos;s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399: 2015-2030, 2022.","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Peyrin-Biroulet L, Chapman JC, Colombel JF, et al.; the SEQUENCE Study Group. Risankizumab versus ustekinumab for moderate-to-severe Crohn&apos;s disease. N Engl J Med 391: 213-223, 2024.","DOI":"10.1056\/NEJMoa2314585"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43: 727-738, 2015.","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Maxwell JR, Zhang Y, Brown WA, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity 43: 739-750, 2015.","DOI":"10.1016\/j.immuni.2015.08.019"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Whibley N, Gaffen SL. Gut-busters: IL-17 ain&apos;t afraid of no IL-23. Immunity 43: 620-622, 2015.","DOI":"10.1016\/j.immuni.2015.10.001"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Fujita S, Honjo H, Takada R, et al. Ulcerative colitis-associated spondyloarthritis successfully treated with infliximab in the absence of enhanced TNF-\u03b1 responses. Intern Med 62: 2493-2497, 2023.","DOI":"10.2169\/internalmedicine.1182-22"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against <i>Helicobacter pylori<\/i> via induction of type I IFN and activation of the ISGF3 signaling pathway. J Clin Invest 120: 1645-1662, 2010.","DOI":"10.1172\/JCI39481"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6139-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:16Z","timestamp":1781926636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6139-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6139-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"6139-25"}}